SLC6A15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer. Issue 8 (10th March 2021)

• Record Type: Journal Article
• Authors: Chen, Yuxin; Li, Hai; Liang, Weiwei; Guo, Yan; Peng, Miaoguan; Ke, Wen; Xiao, Haipeng; Guan, Hongyu; Li, Yanbing
• Is Part Of: Journal of cellular biochemistry. Volume 122:Issue 8(2021)
• Page Start: 814
• Page End: 826
• Publication Date: 2021-03-10
• Subjects: ICAM1 -- invasion -- migration -- papillary thyroid cancer -- SLC6A15; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.29914
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Solute Carrier Family 6 Member 15 (SLC6A15), a sodium‐dependent neutral amino acid transporter, has been found with dysregulated expression in several kinds of cancers. However, the expression pattern and the biological functions of SLC6A15 in papillary thyroid cancer (PTC) remain unknown. In this study, we found that SLC6A15 was downregulated in PTC, which was related to N classification. Ectopic overexpression of SLC6A15 impaired migratory and invasive abilities of PTC cell in vitro. In addition, we identified intercellular adhesion molecule‐1, a vital oncogene in thyroid cancer progression, was involved in the effects of SLC6A15 on PTC cell. These results indicate that SLC6A15 acts as a tumor suppressor and might be a potential therapeutic target in the treatment of PTC. Abstract : Solute Carrier Family 6 Member 15 (SLC6A15) was downregulated in papillary thyroid cancer (PTC) and it was related to N classification. Ectopic overexpression of SLC6A15 impaired the migratory and invasive abilities of PTC cell via intercellular adhesion molecule‐1 downregulation.